RBL PLATFORMS : Ascertaining The Risk-Benefit Analysis Of Bioengineering Pharmacologies Within The Bio-Trigen Theme Cities : XXII SIPO

2021 A.D.E.     SINCE TIME BEGAN Caveat : Forward Thinking Statement : Caveat : IN TRUTH WE TRUST     2021 A.D.E.

Authorized Disclosure By : ESTATE OF DR STITUMAATULWUT HWUNEEM, LLB : SIPO International OPIS

The CBEC Corporate Group Since 1960All Monetary Sums Are Expressed In US Dollars : Certified - Risks / Benefits - Analysis

WHAT WE DO : ADDENDUM : SUSTAINED


Respectfully Published By RALPH CHARLES GOODWIN :  SIPO  Ambassador  OPIS

2021 A.D.E.     SINCE TIME BEGAN Caveat : Forward Thinking Statement : Caveat : IN TRUTH WE TRUST     2021 A.D.E.

HAVE YOU COMPLETED YOUR ULC TODAY ?

BUSINESSWIRE & OTHER TRUTHS